1999
- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-K
Annual Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

For the year ended December 31, 1999 Commission file number 1-815

E. I. DU PONT DE NEMOURS AND COMPANY
(Exact name of registrant as specified in its charter)

DELAWARE 51-0014090
(State or Other Jurisdiction of (I.R.S. Employer Identification No.)
Incorporation or
Organization)

1007 Market Street
Wilmington, Delaware 19898
(Address of principal executive offices)

Registrant's telephone number, including area code: 302-774-1000

Securities registered pursuant to Section 12(b) of the Act
(Each class is registered on the New York Stock Exchange, Inc.):

Title of Each Class

Common Stock ($.30 par value)
Preferred Stock
(without par value-cumulative)
$4.50 Series
$3.50 Series

No securities are registered pursuant to Section 12(g) of the Act.

Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained, to
the best of registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. [ ]

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days. Yes X No

Aggregate market value of voting stock held by nonaffiliates of the
registrant (excludes outstanding shares beneficially owned by directors and
officers; and shares held by DuPont's Flexitrust; and treasury shares) as of
March 6, 2000, was approximately $51.4 billion. As of such date, 1,047,062,136
shares (excludes 5,410,591 shares held by DuPont's Flexitrust and 87,041,427
shares of treasury stock) of the company's common stock, $.30 par value, were
outstanding.

Documents Incorporated by Reference
(Specific pages incorporated are indicated under the applicable Item herein):

Incorporated By
Reference In Part No.
---------------------

The company's 1999 Annual Report to Stockholders...... I, II, and IV
The company's Proxy Statement, dated March 17, 2000,
in connection with the Annual Meeting of Stockholders
to be held on April 26, 2000......................... III

- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------

E. I. DU PONT DE NEMOURS AND COMPANY

----------------

The terms "DuPont" or the "company" as used herein refer to E. I. du Pont de
Nemours and Company and its consolidated subsidiaries (which are wholly owned
or majority-owned), or to E. I. du Pont de Nemours and Company, as the context
may indicate.

----------------

TABLE OF CONTENTS

Page
-----

Part I
Item 1. Business.................................................. 3-9
Item 2. Properties................................................ 9-10
Item 3. Legal Proceedings......................................... 10-11
Item 4. Submission of Matters to a Vote of Security Holders....... 12
Executive Officers of the Registrant...................... 12
Part II
Item 5. Market for Registrant's Common Equity and Related
Stockholder Matters....................................... 12
Item 6. Selected Financial Data................................... 12
Item 7. Management's Discussion and Analysis of Financial
Condition and Results of Operations....................... 13
Item 7A. Quantitative and Qualitative Disclosures About Market
Risk...................................................... 13
Item 8. Financial Statements and Supplementary Data............... 13
Item 9. Changes In and Disagreements With Accountants on
Accounting and Financial Disclosure....................... 13
Part III
Item 10. Directors and Executive Officers of the Registrant........ 14
Item 11. Executive Compensation.................................... 14
Item 12. Security Ownership of Certain Beneficial Owners and
Management................................................ 14
Item 13. Certain Relationships and Related Transactions............ 14
Part IV
Item 14. Exhibits, Financial Statement Schedules, and Reports on
Form 8-K.................................................. 14-17
Signatures.......................................................... 18

Note on Incorporation by Reference

Throughout this report, various information and data are incorporated by
reference to portions of the company's 1999 Annual Report to Stockholders
(those portions are hereinafter referred to as Exhibit 13). Any reference in
this report to disclosures in Exhibit 13 shall constitute incorporation by
reference of that specific material into this Form 10-K.

PART I

Item 1. BUSINESS

DuPont was founded in 1802 and was incorporated in Delaware in 1915. DuPont
is a world leader in science and technology in a range of disciplines
including high-performance materials, specialty chemicals, pharmaceuticals and
biotechnology. The company operates globally through some 20 strategic
business units. Within the strategic business units, approximately 80
businesses manufacture and sell a wide range of products to many different
markets, including the transportation, textile, construction, automotive,
agricultural and hybrid seeds, nutrition and health, pharmaceuticals,
packaging and electronics markets.

In 1999, DuPont completed three major initiatives in line with its strategic
direction. In February, the acquisition of Herberts was finalized for $1.7
billion in cash paid and debt assumed. Herberts was the automotive coatings
business of Hoechst AG, and its acquisition makes DuPont Performance Coatings
the world's largest automotive coatings business. In August, the company
completed its divestiture of the Conoco energy business. In a tax free split
off, DuPont shareholders tendered 147,980,872 shares of DuPont common stock in
exchange for Conoco Class B shares. This transaction culminated a strategic
shift, announced in 1998, to exit the energy business, with realization of $21
billion in value for DuPont shareholders. In October, the company continued
its strategic portfolio realignment with the acquisition of the remaining 80%
of Pioneer Hi-Bred International, Inc. that it did not already own. This
transaction, valued at $7.7 billion, brings to DuPont the largest seed company
in the world. Herberts is part of DuPont's Performance Coatings & Polymers
segment and Pioneer is a stand-alone segment. Conoco Inc. is presented as
discontinued operations in the consolidated financial statements and notes,
and further discussed in the Discontinued Operations section below and in
Exhibit 13. Consistent with this presentation, essentially all information in
this report is provided on a continuing operations basis unless otherwise
noted.

The company's strategic business units have been aggregated into nine
reportable segments--Agriculture & Nutrition, Nylon Enterprise, Performance
Coatings & Polymers, Pharmaceuticals, Pigments & Chemicals, Pioneer, Polyester
Enterprise, Specialty Fibers, and Specialty Polymers. The following pages and
Exhibit 13 provide perspective on these nine segments. Excluded is a tenth
segment, "Other." This segment represents less than 2% of total 1999 segment
sales and consists of the company's photomasks, safety resources, and global
services businesses, and divested businesses including certain printing and
publishing products and coal. Financial data for the "Other" segment is
provided in Note 28, "Industry Segment Information," in Exhibit 13.

The company and its subsidiaries have operations in about 65 countries
worldwide and, as a result, about 49% of consolidated sales are derived from
sales outside the United States, based on the location of the customer.
Subsidiaries and affiliates of DuPont conduct manufacturing, seed production,
or selling activities; and some are distributors of products manufactured by
the company. Total worldwide employment at year-end 1999 was about 94,000
people.

Discontinued Operations

On September 28, 1998, the company announced that the Board of Directors had
approved a plan to divest the company's 100%-owned petroleum business, Conoco
Inc. On October 21, 1998, the company's interest in Conoco was reduced to 69.5
% following an initial public offering of Conoco Class A common stock. On
August 6, 1999, the company completed the planned divestiture through a tax-
free split off whereby the company exchanged its 436,543,573 shares of Conoco
Class B common stock for 147,980,872 shares of DuPont common stock. The
company's consolidated financial statements and notes report its former
petroleum business as discontinued operations.

The following information describing the business of the company can be
found on the indicated pages of Exhibit 13:

Item Page(s)
---- -------

Discussion of Business Developments in 1999:
Chairman's Letter.................................................... 2- 5*
Segment Reviews:
Business Discussions, Principal Products and Principal Markets:
Agriculture & Nutrition............................................ 16-17
Nylon Enterprise................................................... 17-18
Performance Coatings & Polymers.................................... 18-19
Pharmaceuticals.................................................... 19-20
Pigments & Chemicals............................................... 20-21
Pioneer............................................................ 21-22
Polyester Enterprise............................................... 22-23
Specialty Fibers................................................... 23-24
Specialty Polymers................................................. 24-25
Total Segment Sales, Intersegment Transfers, After-Tax Operating
Income, and Segment Net Assets for 1999, 1998, and 1997............. 68-71
Geographic Information:
Net Sales and Net Property 1999, 1998, and 1997...................... 68

- --------
* Excludes the photographs, captions, and margin notes on pages 2 to 5.

Sources of Supply

The company utilizes numerous firms as well as internal sources to supply a
wide range of raw materials, energy, supplies, services and equipment. To
assure availability, the company maintains multiple sources for most raw
materials, including hydrocarbon feedstocks, and for fuels. Large volume
purchases are generally procured under competitively priced supply contracts.

With the exception of the Agriculture & Nutrition, Pharmaceuticals, and
Pioneer segments, a majority of sales in the segments' businesses is dependent
on hydrocarbon feedstocks derived from crude oil and natural gas. Current
hydrocarbon feedstock requirements are met by purchases from major petroleum
companies. DuPont's joint venture with Equistar Chemicals, LP manufactures and
supplies a significant portion of the company's requirements for ethylene
glycol.

The major purchased commodities, raw materials, and supplies for reportable
segments in 1999 are listed below:

Performance
Agriculture & Coatings Pigments & Specialty
Nutrition & Polymers Chemicals Fibers
- ---------------- ---------------- ---------------- ----------------
acetaldoxime adipic acid ammonia acetylene
cyanamide butadiene chlorine isophthaloyl
dichlorophenol chlorine chloroform chloride
isocyanate cyclohexane coke metaphenylenediamine
methyl mercaptan ethylene fluorspar MDI
packaging materials fiberglass hydrofluoric paraphenylenediamine
soybean flake hydrocarbon solvents acid polyethylene
isocyanate resins isophthalic terephthaloyl
melamine resins acid chloride
Nylon methanol methanol
Enterprise packaging materials perchloroethylene Specialty
- ---------------- pigments sodium Polymers
adipic acid polyethylene hydroxide ----------------
ammonia ultra violet sulfur acetic acid
butadiene light stabilizer titanium ore alumina trihyclrate
cyclohexane ethane
natural gas Polyester methacrylic
Pharmaceuticals Enterprise acid
---------------- ---------------- polyethylene
efavirenz acetic acid
losartan potassium dimethyl
molybdenum-99 terephthalate
warfarin sodium ethylene glycol
copper-midi packaging
naltrexone materials
hydrochloride paraxylene
purified
terephthalic acid

Pioneer
- ----------
The Pioneer segment, in the hybrid seed industry, has seed production
facilities located throughout the world, in both the Northern and Southern
Hemispheres. In the production of its parent and commercial seed, Pioneer
generally provides the seed stock, detasseling and roguing labor, and certain
other production inputs. The balance of the labor, equipment, and inputs are
supplied by independent growers. Pioneer believes the availability of growers,
parent seed stock, and other inputs necessary to produce its commercial seed
is adequate for planned production levels. The principal risk in the
production of seed is the environment, with weather being the single largest
variant. Pioneer lessens this risk by distributing production across many
locations around the world. Due to its global presence, the company can engage
in seed production year-round.

In addition, during 1999, the company consumed substantial amounts of
electricity and natural gas for energy.

In June 1997, DuPont formed ten-year alliances with Computer Sciences
Corporation (CSC) and Andersen Consulting. CSC operates a majority of the
company's global information systems and technology infrastructures and
provides selected applications and software services. Andersen Consulting
provides information systems solutions designed to enhance DuPont's
manufacturing, marketing, distribution and customer service.

Patents and Trademarks

The company believes that its patent and trademark estate provides it with a
significant competitive advantage and has established an international network
of attorneys and agents to procure and protect its patents and trademarks.

The company owns and is licensed under various patents, which expire from
time to time, covering many products, processes and product uses. The actual
protection afforded by these patents varies from country to country and
depends upon the scope of coverage of each individual patent as well as the
availability of legal remedies in each country. The company owns about 18,000
patents which are filed worldwide and has over 16,000 applications for patents
pending. In 1999, the company was granted almost 350 U.S. patents and almost
1,500 international patents. No individual patent is of material importance to
any of the company's segments. However, the company's rights under its patents
and licenses, as well as the products made and sold under them, are important
to the company as a whole and, to varying degrees, important to each segment.
Patent information related to Crop Protection (CP) is in Exhibit 13 on page 17
at the "Outlook" part of the Agriculture & Nutrition segment review.

Patent protection is important to the ability of the DuPont Pharmaceuticals
Company ("DuPont Pharmaceuticals") to successfully commercialize its products.
DuPont Pharmaceuticals owns or is licensed under a number of patents and
pending patent applications in the United States and other countries, relating
to its marketed products and its development pipeline. The patent protection
for Coumadin(R) (warfarin sodium) has expired. DuPont Pharmaceuticals is
exclusively licensed in the United States, Canada and certain European
countries under Merck & Co.'s patents covering Sustiva(TM) (efavirenz). The
U.S. patents covering the Sustiva(TM) compound and use of Sustiva(TM) for the
treatment of HIV infection expire in 2013 and 2014, respectively. DuPont has
exclusively licensed marketing rights for Cozaar(R) (losartan potassium) and
Hyzaar(R) (losartan potassium, hydrochlorothiazide) to Merck & Co. Inc. under
the patents covering these products. The U.S. patents covering Cozaar(R) and
Hyzaar(R) compounds, pharmaceutical formulation and use for treatment for
hypertension expire in 2009.

The environment in which Pioneer and the rest of the hybrid seed industry
compete is increasingly affected by new patents, patent positions and patent
lawsuits. Pioneer believes that its current intellectual property positions,
technologies, germplasm and sales force put it in a good position to freely
develop and commercialize the products Pioneer will need to compete
effectively. No single piece of intellectual property owned by Pioneer is
vitally important to its business. However, Pioneer's total patent position
relating to biotechnology, including the area of genetically engineering
insect, disease and herbicide resistance into crops, may be significant to its
ability to compete in the future. Pioneer, as well as others in the industry,
have applied for and been granted a substantial number of patents in this
area. If existing and future biotechnology patents are upheld, it is uncertain
if the holders of these patents will allow the technology to be licensed to
others in the industry. If licenses are granted, it is uncertain whether they
will be based on commercially reasonable terms. Pioneer will review carefully
all requests for licenses to its technology and will grant access when it is
commercially prudent to do so. Pioneer is involved in several lawsuits, both
as plaintiff and defendant, concerning intellectual property rights related
primarily to corn and soybean products. The ultimate outcome of all of this
litigation could be significant to the results of operations of the Pioneer
segment during the period recognized, but management does not anticipate that
it will have a material adverse effect on the company's consolidated financial
position or liquidity.

The company has more than 2,000 individual trademarks and brands for its
products and services which are registered in various countries throughout the
world. Ownership rights in trademarks do not expire if the trademarks are
continued in use and properly protected. The company has a number of
trademarks which have significant recognition at the consumer level; many are
the most recognized brands in their categories. Examples include the DuPont
Oval, Lycra(R) spandex, Corian(R) surfaces, Stainmaster(R) carpets, Teflon(R)
fluoropolymers, films, fabric protector and dispersions, and Pioneer(R) brand
seeds. The company's rights under its trademarks are important to the company
as a whole and, to varying degrees, important to each industry segment. All of
DuPont Pharmaceuticals' significant products are sold under trademarks which
are protected by registration in the United States and other countries in
which its products are marketed. DuPont Pharmaceuticals considers these
trademarks in the aggregate to be of material importance to the operation of
its business.

Seasonality

In general, sales of the company's products, outside of the Agriculture &
Nutrition and Pioneer segments, are not substantially affected by seasonality.
The Agriculture & Nutrition segment business is strongest in the first half of
the year, particularly the second quarter. The Pioneer segment's seed business
is also highly seasonal. Substantially all seed sales and earnings are made
during the first half of the year. Pioneer generally operates at a loss during
the third and fourth quarters of the year.

Due to the seasonal nature of the seed business, Pioneer segment's inventory
is at its highest level at the end of the calendar year, and is sold down in
the first and second quarters. Trade receivables in the Agricultural &
Nutrition and Pioneer segments are at a low point at year-end and increase
through the selling season to peak at the end of second quarter.

Marketing

With the exception of Pioneer, most products are marketed primarily through
DuPont's sales force, although in some regions more emphasis is placed on
sales through distributors. In North America, the majority of Pioneer(R) brand
seed is marketed through independent sales representatives. In areas outside
the traditional corn belt, seed products are often marketed through dealers
and distributors who handle other agricultural supplies. Pioneer products are
marketed outside North America through a network of subsidiaries, joint
ventures, and independent producer-distributors.

Major Customers

The company's sales are not materially dependent on a single customer or
small group of customers. The Nylon Enterprise and the Performance Coatings &
Polymers segments, however, have several large customers in their respective
industries that are important to these segments' operating results. In 1999
for the Pharmaceuticals segment, ten wholesale distributors of the DuPont
Pharmaceuticals Company comprised 68% of gross sales.

Competition

Businesses in DuPont's nine reportable segments compete on a variety of
factors such as price, product quality or specifications, customer service and
breadth of product line, depending on the characteristics of the particular
market involved.

Principal competitors for all segments except Pharmaceuticals, Pioneer, and
Agricultural & Nutrition include major chemical companies based in the United
States, Europe, Japan, China and other Asian nations. Competitors offer a
comparable range of products from agricultural, commodity and specialty
chemicals to plastics and fibers products. The company also competes in
certain product markets with smaller, more specialized firms. In addition, the
company competes with petrochemical operations in oil-producing countries.

The Pharmaceuticals segment faces competition from both ethical
pharmaceutical companies which produce drugs that treat indications treated by
DuPont's products and from generic companies which produce drugs that are the
generic equivalents of DuPont's products.

The Pioneer segment, in the hybrid seed industry, is characterized by
competition based primarily on product performance and price. Pioneer's
objective is to produce products that consistently out-perform the competition
and therefore command a premium price.

Research and Development

The company performs research and development in support of strategic
business units in all nine reportable segments.

The highest concentration of research is carried out at several large
research centers in and around Wilmington, Delaware, which are primary
research locations for eight of the nine reportable segments (all except
Pioneer). Among these, the Experimental Station laboratories engage in
exploratory and applied research, the Chestnut Run laboratories focus on
applications research, and the Stine-Haskell Research Center conducts
agricultural product research and toxicological research on company products
to assure they are safe for manufacture and use. In addition, research for
these eight segments is conducted in the United States at over 40 sites in 18
states at either dedicated research facilities or manufacturing plants. DuPont
also operates an increasing number of research facilities at locations outside
the United States in countries such as Belgium, Canada, France, Germany,
Japan, Luxembourg, Mexico, The Netherlands, Spain, Switzerland and the United
Kingdom, reflecting the company's global interests.

The Pioneer segment carries out research and product development to develop
hybrids of corn, sorghum and sunflower, and varieties of soybean, alfalfa,
wheat, and canola for worldwide markets. Pioneer operates more than 110
primary research locations involved in developing and testing new products.
Hybrids and varieties are developed at these primary research locations and
tested at thousands of other locations.

Relative to historical levels, the company is placing increasing emphasis on
bioscience-related research and development through the Agriculture &
Nutrition, Pharmaceuticals, and Pioneer segments. Research and development
expense is expected to increase in 2000.

The objectives of the company's research and development programs are to
discover new products, processes and business opportunities in relevant
fields, and to improve existing products and processes. Each strategic
business unit of the company funds research and development activities to
support its business mission. The corporate laboratories are responsible for
assuring that leading-edge science and engineering concepts are identified and
diffused throughout the DuPont technical community. All research and
development activities are coordinated by senior research and development
management through a corporate technology council to ensure that technical
activities are consistent with business and corporate plans, and that the core
technical competencies underlying DuPont's current and future businesses
remain healthy and continue to provide competitive advantages.

Annual research and development expense and such expense shown "As Percent
of Sales" for the five years 1995 through 1999 are included under the heading
"General" of the Five-Year Financial Review on page 73 of Exhibit 13.

Environmental Matters

Information relating to environmental matters is included in two areas of
Exhibit 13: (1) "Management's Discussion and Analysis" on pages 39-41, and (2)
Notes 1 and 26 to the financial Statements on pages 47-48 and 66-67,
respectively.

Cautionary Statements Under The Private Securities Litigation Reform Act of
1995

Forward-Looking Statements

This presentation contains forward-looking statements which may be
identified by their use of words like "plans," "expects," "will,"
"anticipates," "intends," "projects," "estimates" or other words of similar
meaning. All statements that address expectations or projections about the
future, including statements about the company's strategy for growth, product
development, market position, expenditures, financial results are forward-
looking statements.

Forward-looking statements are based on certain assumptions and expectations
of future events. The company cannot guarantee that these assumptions and
expectations are accurate or will be realized. In addition

to the factors discussed in this report, the following are some of the
important factors that could cause the company's actual results to differ
materially from those projected in any such forward-looking statements:

. The company operates in approximately 65 countries worldwide and derives
about half of its revenues from sales outside the United States. Changes
in the laws or policies of other governmental and quasi-governmental
activities in the countries in which the company operates could affect
its business in the country and the company's results of operations. In
addition, economic factors (including inflation and fluctuations in
interest rates, foreign currency exchange rates) and competitive factors
(such as greater price competition or a decline in U.S. or European
industry sales from slowing economic growth) in those countries could
affect the company's revenues, expenses and results.

. The company's growth objectives are largely dependent on its ability to
renew its pipeline of new products and to bring those products to
market. This ability may be adversely affected by difficulties or delays
in product development such as the inability to: identify viable new
products; successfully complete clinical trials of new pharmaceuticals;
obtain relevant regulatory approvals, which may include approval from
the Food and Drug Administration; obtain adequate intellectual property
protection; or gain market acceptance of the new products.

. As part of its strategy for growth, the company has made and may
continue to make acquisitions, divestitures and alliances. There can be
no assurance that these will be completed or beneficial to the company.

. To a significant degree, results in the company's Agriculture &
Nutrition and Pioneer segments reflect changes in agricultural
conditions, including weather and government programs. These results
also reflect the seasonality of sales of agricultural products; highest
sales in the United States occur in the first half of the year,
particularly the second quarter. In addition, demand for products
produced in these segments may be affected by market acceptance of
genetically modified organisms.

. The company has undertaken and may continue to undertake productivity
initiatives, including organizational restructurings, to improve
productivity and generate cost savings. There can be no assurance that
these will be completed or beneficial to the company. Also there can be
no assurance that any estimated cost savings from such activities will
be realized.

. The company's facilities are subject to a broad array of environmental
laws and regulations. The costs of complying with complex environmental
laws and regulations as well as internal voluntary programs, are
significant and will continue to be so for the foreseeable future. The
company's accruals for such costs and liabilities may not be adequate
since the estimates on which the accruals are based depend on a number
of factors including the nature of the allegation, the complexity of the
site, the nature of the remedy, the outcome of discussions with
regulatory agencies and other potentially responsible parties (PRPs) at
multi-party sites, and the number and financial viability of other PRPs.

. The company's results of operations could be affected by significant
litigation adverse to the company including product liability claims,
patent infringement claims and antitrust claims.

The foregoing list of important factors is not inclusive, or necessarily in
order of importance.

Item 2. PROPERTIES

The company owns and operates manufacturing, processing, production,
marketing, and research and development facilities worldwide.

DuPont's corporate headquarters is located in Wilmington, Delaware. In
addition, the company operates sales offices, regional purchasing offices,
distribution centers, and various other specialized service locations.

Further information regarding properties is included in Exhibit 13 in the
Segment Reviews on pages 16-25. Information regarding research and development
facilities is incorporated by reference to Item 1, Business--

Research and Development on pages 7-8 of this report. Additional information
with respect to the company's property, plant and equipment, and leases is
contained in Notes 13 and 26 to the company's consolidated financial
statements on pages 55 and 66-67, respectively, in Exhibit 13.

Approximately 71% of the property, plant and equipment related to operations
in the company's nine reportable segments is located in the United States and
Puerto Rico. This investment is located at some 75 sites, principally in
Texas, Delaware, Virginia, North Carolina, Tennessee, West Virginia, and South
Carolina. The principal locations within these states are as follows:

North
Texas Delaware Virginia Carolina
- ---------------- ----------- ----------- ------------

Beaumont Edge Moor Front Royal Fayetteville
Corpus Christi Newark Hopewell Kinston
LaPorte Seaford James River Raleigh
Orange Richmond Wilmington
Victoria Waynesboro

West South
Tennessee Virginia Carolina
- ---------------- ----------- -----------

Chattanooga Belle Camden
Memphis Martinsburg Charleston
New Johnsonville Parkersburg Florence
Old Hickory

Property, plant and equipment outside the United States and Puerto Rico is
located at about 70 sites, principally in the United Kingdom, Canada, The
Netherlands, Germany, Singapore, China, Luxembourg, Spain, Taiwan, Mexico,
France, Japan, Brazil, Belgium, Argentina and Republic of Korea.

The company's plants and equipment are well maintained and in good operating
condition. Sales as a percent of capacity were 83% in 1999, 82% in 1998, and
88% in 1997. These properties are directly owned by the company except for
some auxiliary facilities and miscellaneous properties, such as certain
buildings and transportation equipment, which are leased. Although no title
examination of the properties has been made for the purpose of this report,
the company knows of no material defects in title to any of these properties.

Item 3. LEGAL PROCEEDINGS

In 1991, DuPont began receiving claims by growers that use of Benlate(R) 50
DF fungicide had caused crop damage. Based on the belief that Benlate(R) 50 DF
would be found to be a contributor to the claimed damage, DuPont began paying
crop damage claims. In 1992, after 18 months of extensive research, DuPont
scientists concluded that Benlate(R) 50 DF was not responsible for plant
damage reports received since March 1991. Concurrent with these research
findings, DuPont stopped paying claims. DuPont since has been served with
several hundred lawsuits most of which were disposed of by trial, dismissal or
settlement. As of mid-March 2000, approximately 150 of the cases are pending.
Most of these lawsuits were filed by growers who allege plant damage from
using Benlate(R) 50 DF although some include claims for alleged damage to
shrimping operations and a smaller number of cases include claims for alleged
personal injuries. Also, many of these cases include general allegations of
fraud and misconduct. In addition, a securities fraud class action was filed
in September 1995 by a shareholder in federal district court in Florida
against the company and the then-Chairman. This action is still pending. The
plaintiff in this case alleges that DuPont made false and misleading
statements and omissions about Benlate(R) 50 DF, with the alleged effect of
inflating the price of DuPont's stock between June 19, 1993, and January 27,
1995. The district court has certified the case as a class action. Discovery
is proceeding. Also pending is a shareholder derivative action filed in
Georgia federal district court which alleges that DuPont's Board of Directors
breached various duties in connection with the Benlate(R) 50 DF litigation. A
motion to dismiss the complaint was filed. Certain plaintiffs who have
previously settled with the company have filed cases alleging fraud and other
misconduct relating to the litigation and settlement of Benlate(R) 50 DF
claims. Approximately 40

such cases are pending. These cases are in various stages of proceedings in
trial and appellate courts in Florida and Hawaii. DuPont continues to believe
that Benlate(R) 50 DF did not cause the damages alleged in these cases and
denies the allegations of fraud and misconduct. DuPont intends to defend
itself in ongoing matters and in any additional cases that may be filed or
reopened. The ultimate liabilities from Benlate(R) 50 DF lawsuits may be
significant to the company's results of operations, particularly in the Crop
Protection business, in the period recognized, but management does not
anticipate that they will have a material adverse effect on the company's
consolidated financial position or liquidity.

The company's balance sheets reflect accruals for estimated costs associated
with this matter. Adverse changes in these estimated costs could result in
additional future charges.

On October 7, 1994, the Environmental Protection Agency (EPA) filed an
administrative complaint against DuPont proposing to assess $1.9 million in
civil penalties for distributing triazine herbicides with product labels that
the EPA alleges were not in compliance with its Worker Protection Standards.
The labels were submitted to the EPA for approval in July 1993 and accepted by
the EPA in November. However, in March of 1994, the EPA notified DuPont of
alleged errors in the labels. DuPont has cooperated with the EPA in making
label changes and has issued supplemental labeling for all products that had
been distributed. An administrative law judge has issued an initial
determination affirming the penalties. DuPont believes the proposed penalties
are unwarranted and is contesting the complaint and proposed civil penalty in
an EPA administrative proceeding.

On September 2, 1997, the U.S. Department of Justice (DOJ) filed suit
against DuPont related to an August 1995 oleum release from DuPont's plant in
Wurtland, Kentucky. DuPont previously paid a $125,000 fine and agreed to
undertake supplemental environmental projects, related to the oleum release,
valued at $460,000. In its complaint, the DOJ alleges violations under Section
112(r) of the Clean Air Act, Section 103(a) of the Comprehensive Environmental
Response, Compensation and Liability Act (CERCLA) and Section 304(a)(1) of the
Emergency Planning and Community Right-to-Know Act. DOJ offered to settle this
action for $2.7 million. DuPont denies these alleged violations, believes that
DOJ's settlement offer is inappropriate and excessive and plans to contest
this action by DOJ.

By letter dated July 13, 1999, the U.S. Department of Justice (DOJ) provided
"formal notice" to DuPont that, due to the May 1997 HF release, DOJ intended
to bring a "federal court action" against DuPont under the Clean Air Act (CAA)
Section 112(r)--General Duty Clause. On May 19, 1997, approximately 11,500
pounds of a hydrogen fluoride (HF)/tar mixture was released from DuPont's
Louisville, Kentucky, fluoroproducts facility. This release lasted about 40
minutes. There were no on site injuries, and only one off-site person reported
any exposure. No toxic tort suits were filed as a result of this release.
DuPont's incident investigation concluded that an inadequate valve stem design
was a key factor contributing to the release (the valve stem twisted and the
valve indicted it was in a closed position, when it was actually open).
DuPont's process isolation procedures were also reviewed and modified as a
result of this incident. DOJ proposed a settlement prior to filing its action
for $1.7 million. DuPont sought and received a meeting with EPA and DOJ in
September 1999. Settlement discussions are ongoing. DuPont will contest the
proposed $1.7 million fine as excessive and unreasonable because there was no
environmental harm or human health impacts associated with the May 1997
incident.

The Indiana Departments of Natural Resources and Environmental Management
and the United States Department of Interior are in the process of conducting
a natural resource damage assessment of the Grand Calumet River and the
Indiana Harbor Canal system under CERCLA and the Oil Pollution Act (OPA). The
company's plant in East Chicago, Indiana, which discharges industrial
wastewater into these waterways, was identified as one of 17 entities
potentially responsible parties (PRPs) for the cost of the assessment and any
determined natural resource damages. The trustees recently indicted that their
preferred remedy is to dredge the entire Grand Cal/Indiana Harbor system.
DuPont has joined with eight other PRPs to contest the remedy. A settlement
offer has been tendered to the trustees and negotiations are ongoing.

Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.

EXECUTIVE OFFICERS OF THE REGISTRANT

The following is a list, as of March 6, 2000, of the company's executive
officers.

Executive
Officer
Age Since
------- ---------

Chairman of the Board of Directors and Chief Executive
Officer
Charles O. Holliday, Jr.(1)................................ 51 1992
Other Executive Officers:
Richard R. Goodmanson, Executive Vice President and Chief
Operating Officer......................................... 52 1999
Joseph A. Miller, Jr., Senior Vice President and Chief
Science & Technology Officer.............................. 58 1994
Stacey J. Mobley, Senior Vice President, Chief
Administrative Officer and General Counsel................ 54 1992
Gary M. Pfeiffer, Senior Vice President and Chief Financial
Officer................................................... 50 1997
- --------
(1) Member of the Board of Directors.

The company's executive officers are elected or appointed for the ensuring
year or for an indefinite term, and until their successors are elected or
appointed. With the exception of Mr. Goodmanson, each officer named above has
been an officer or an executive of DuPont, its subsidiaries, or an affiliate
during the past five years. Prior to joining DuPont, Mr. Goodmanson was
president and chief executive officer of America West Airlines from 1996 to
1999. He was senior vice president of operations for Frito-Lay Inc. from 1992-
1996, and he was a principal at McKinsey & Company, Inc. from 1980 to 1992.

PART II

Information with respect to the following Items can be found on the
indicated pages of Exhibit 13 if not otherwise included herein.

Item 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

The company's common stock is listed on the New York Stock Exchange, Inc.
(symbol DD) and certain non-U.S. exchanges. The number of record holders of
common stock was 139,835 at December 31, 1999, and 138,138 at March 6, 2000.

Page(s)
-------

Quarterly Financial Data:
Dividends Per Share of Common Stock........................ 72
Market Price of Common Stock (High/Low).................... 72

Item 6. SELECTED FINANCIAL DATA

Five-Year Financial Review:
Summary of Operations...................................... 73
Financial Position at Year End............................. 73
General.................................................... 73

Item 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS

Page(s)
-------

Chairman's Letter..................................................... 2-5*
Management's Discussion and Analysis:
Analysis of Continuing Operations................................... 14-15
Discontinued Operations............................................. 15-16
Segment Reviews..................................................... 16-26
Financial Condition................................................. 26-27
Purchased In-Process Research and Development....................... 28-36
Financial Instruments............................................... 36-38
Year 2000 Readiness Disclosure...................................... 38
European Monetary Union............................................. 39
Environmental Matters............................................... 39-41
Forward-Looking Statements.......................................... 41
- --------
*Excludes the photographs, captions, and margin notes on pages 2 to 5.

Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Management's Discussion and Analysis:
Financial Instruments
Derivatives and Other Hedging Instruments......................... 36
Foreign Currency Risk............................................. 37
Interest Rate Risk................................................ 38
Commodity Price Risk and Trading.................................. 38

Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

Financial Statements:
Report of Independent Accountants................................... 42
Consolidated Income Statement for 1999, 1998, and 1997.............. 43
Consolidated Balance Sheet as of December 31, 1999 and December 31,
1998............................................................... 44
Consolidated Statement of Stockholders' Equity for 1999, 1998 and
1997............................................................... 45
Consolidated Statement of Cash Flows for 1999, 1998 and 1997........ 46
Notes to Financial Statements....................................... 47-71
Quarterly Financial Data and related notes for the following items for
the two years 1999 and 1998:
Sales............................................................... 72
Cost of Goods Sold and Other Expenses............................... 72
Income (Loss) from Continuing Operations............................ 72
Income from Discontinued Operations................................. 72
Net Income (Loss)................................................... 72
Basic Earnings Per Share of Common Stock............................ 72
Diluted Earnings Per Share of Common Stock.......................... 72
Dividends Per Share of Common Stock................................. 72
Market Price of Common Stock........................................ 72

Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE

None.

PART III

Information with respect to the following Items is incorporated by reference
to the pages indicated in the company's 1999 Annual Meeting Proxy Statement
dated March 17, 2000, filed in connection with the Annual Meeting of
Stockholders to be held April 26, 2000. However, information regarding
executive officers is contained in Part I of this report (page 12) pursuant to
General Instruction G of this form.

Item 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT

Page(s)
-------

Election of Directors................................................... 4-7
Compliance With the Securities Exchange Act............................. 9

Item 11. EXECUTIVE COMPENSATION

Compensation of Directors............................................... 2-3
Compensation and Stock Option Information............................... 12-15
Retirement Benefits..................................................... 16-17

Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

Beneficial Ownership of Securities...................................... 8-9

Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

Election of Directors................................................... 4-7

PART IV

Item 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K

(a) Financial Statements, Financial Statement Schedule and Exhibits

1. Financial Statements. (See listing at Part II, Item 8 of this report
regarding financial statements, which are incorporated by reference to
Exhibit 13.)

2. Financial Statement Schedule.

Report of Independent Accountants on Financial Statement Schedule
Schedule II--Valuation and Qualifying Accounts and Reserves.

The following should be read in conjunction with the previously referenced
Financial Statements:

Financial Statement Schedules listed under SEC rules but not included in
this report are omitted because they are not applicable or the required
information is shown in the consolidated financial statements or notes
thereto incorporated by reference.

Condensed financial information of the parent company is omitted because
restricted net assets of consolidated subsidiaries do not exceed 25% of
consolidated net assets. Footnote disclosure of restrictions on the ability
of subsidiaries and affiliates to transfer funds is omitted because the
restricted net assets of subsidiaries combined with the company's equity in
the undistributed earnings of affiliated companies does not exceed 25% of
consolidated net assets at December 31, 1999.

Separate financial statements of affiliated companies accounted for by
the equity method are omitted because no such affiliate individually
constitutes a 20% significant subsidiary.

3. Exhibits

The following list of exhibits includes both exhibits submitted with this
Form 10-K as filed with the SEC and those incorporated by reference to other
filings:

Exhibit
Number Description
------- -----------

3.1 Company's Restated Certificate of Incorporation, filed May 29, 1997
(incorporated by reference to the company's filing on Form 8-K on June
13, 1997.)
3.2 Company's Bylaws, as last revised January 1, 1999 (incorporated by
reference to Exhibit 3.2 of the company's Annual Report on Form 10-K
for the year ended December 31, 1998).
4 The company agrees to provide the Commission, on request, copies of
instruments defining the rights of holders of long-term debt of the
company and its subsidiaries.
10.1* Company's Corporate Sharing Plan, as last amended August 28, 1991
(incorporated by reference to Exhibit 10.1 of the company's Annual
Report on Form 10-K for the year ended December 31, 1996).
10.2* The DuPont Stock Accumulation and Deferred Compensation Plan, as last
amended April 29, 1998 (incorporated by reference to Exhibit 10.3 of
the company's Quarterly Report on Form 10-Q for the period ended March
31, 1998).
10.3* Company's Supplemental Retirement Income Plan, as last amended
effective June 4, 1996 (incorporated by reference to Exhibit 10.3 of
the company's Annual Report on Form 10-K for the year ended December
31, 1996).
10.4* Company's Pension Restoration Plan, as last amended effective June 4,
1996 (incorporated by reference to Exhibit 10.4 of the company's
Annual Report on Form 10-K for the year ended December 31, 1996).
10.5* Company's Stock Performance Plan, as last amended effective January
28, 1998 (incorporated by reference to Exhibit 10.1 of the company's
Quarterly Report on Form 10-Q for the period ended March 31, 1998).
10.6* Company's Variable Compensation Plan, as last amended effective April
30, 1997 (incorporated by reference to Exhibit 10.7 of the company's
Quarterly Report on Form 10-Q for the quarter ended September 30,
1997).
10.7* Company's Salary Deferral & Savings Restoration Plan effective April
26, 1994.
10.8* Company's 1995 Corporate Sharing Plan, adopted by the Board of
Directors on January 25, 1995.
10.9* Company's 1997 Corporate Sharing Plan, adopted by the Board of
Directors on January 29, 1997 (incorporated by reference to Exhibit
10.11 of the company's Annual Report on Form 10-K for the year ended
December 31, 1996).
10.10* Company's Retirement Income Plan for Directors, as last amended August
1995 (incorporated by reference to Exhibit 10.12 of the company's
Quarterly Report on Form 10-Q for the quarter ended March 31, 1997).
10.11* Letter Agreement and Employee Agreement, dated as of April 22, 1999,
between the company and R. R. Goodmanson.
10.12 Company's Tax Sharing Agreement dated October 27, 1998, by and among
the company and Conoco Inc., formerly known as Conoco Energy Company
(incorporated by reference to Exhibit 10.13 of the company's Annual
Report on Form 10-K for the year ended December 31, 1998).
11 Statement re calculation of earnings per share.
12 Statement re computation of the ratio of earnings to fixed charges.
12.1 Statement re computation of the ratio of earnings to fixed charges--
Pro Forma.

- --------
* Management contract or compensatory plan or arrangement required to be filed
as an exhibit to this Form 10-K.

Exhibit
Number Description
------- -----------

13 The Letter to Shareholders; Management's Discussion and Analysis; and
Financial Information Section of the Annual Report to Shareholders for
the year ended December 31, 1999, which are furnished to the
Commission for information only, and not filed except as expressly
incorporated by reference in this Report.
21 Subsidiaries of the Registrant.
23 Consent of Independent Accountants.
27* Financial Data Schedule--year ended December 31, 1999.
27.1* Restated Financial Data Schedule--year ended December 31, 1998.
27.2* Restated Financial Data Schedule--year ended December 31, 1997.
27.3* Restated Financial Data Schedule--quarter ended March 31, 1999.
27.4* Restated Financial Data Schedule--quarter ended June 30, 1999.
27.5* Restated Financial Data Schedule--quarter ended September 30, 1999.
27.6* Restated Financial Data Schedule--quarter ended March 31, 1998.
27.7* Restated Financial Data Schedule--quarter ended June 30, 1998.
27.8* Restated Financial Data Schedule--quarter ended September 30, 1998.

- --------
* Filed electronically only.

(b) Reports on Form 8-K

Reports on Form 8-K:

(1) On October 8, 1999, a Current Report on Form 8-K was filed in
connection with Debt and/or Equity Securities that may be offered on a
delayed or continuous basis under Registration Statements on Form S-3 (No.
33-53327, No. 33-61339, No. 33-60069 and No. 333-86363). Under Item 5,
"Other Events," the Registrant filed a press release entitled "DuPont
Announces Final Proration Factor For Merger With Pioneer Hi-Bred
International, Inc."

(2) On October 8, 1999, a Current Report on Form 8-K was filed in
connection with Debt Securities that may be offered on a delayed or
continuous basis under its Registration Statements on Form S-3 (No. 33-
53327, No. 33-61339, No. 33-60069 and No. 333-86363). Under Item 5, "Other
Events," the Registrant filed a press release entitled "DuPont Plans to
Acquire CombiChem to Assist in Drug Discovery."

(3) On October 18, 1999, a Current Report on Form 8-K was filed in
connection with Debt and/or Equity Securities that may be offered on a
delayed or continuous basis under Registration statements on Form S-3 (No.
33-53327, No. 33-61339, No. 33-60069 and No. 333-86363). Under Item 2,
"Acquisition or Disposition of Assets," the Registrant filed information
related to the merger of DuPont and Pioneer Hi-Bred International, Inc.

(4) On October 20, 1999, a Current Report on Form 8-K was filed in
connection with Debt Securities that may be offered on a delayed or
continuous basis under its Registration Statements on Form S-3 (No. 33-
53327, No. 33-61339, No. 33-60069 and No. 333-86363). Under Item 7,
"Financial Statements and Exhibits," the Registrant filed a press release
entitled "DuPont Reports Third Quarter 1999 Earnings."

(5) On January 6, 2000, a Current Report on Form 8-K was filed in
connection with Debt and/or Equity Securities that may be offered on a
delayed or continuous basis under Registration Statements on Form S-3 (No.
33-53327, No. 33-61339, No. 33-60069 and No. 333-86363). Under Item 5,
"Other Events," the Registrant filed a press release entitled "Landgraf
Named CEO of DuPont Pharmaceuticals Company."

(6) On January 26, 2000, a Current Report on Form 8-K was filed in
connection with Debt Securities that may be offered on a delayed or
continuous basis under its Registration Statements on Form S-3 (No. 33-
53327, No. 33-61339, No. 33-60069 and No. 333-86363). Under Item 7,
"Financial Statements and Exhibits," the Registrant filed a press release
entitled "DuPont Reports Fourth Quarter And Full Year 1999 Earnings."

(7) On February 22, 2000, a Current Report on Form 8-K was filed in
connection with Debt Securities that may be offered on a delayed or
continuous basis under its Registration Statements on Form S-3 (No. 33-
53327, No. 33-61339, No. 33-60069 and No. 333-86363). Under Item 5, "Other
Events," the Registrant filed a press release entitled "DuPont and Internet
Capital Group Partner to Accelerate E-Commerce Development in Major
Industrial Markets."

(8) On February 23, 2000, a Current Report on Form 8-K was filed in
connection with Debt Securities that may be offered on a delayed or
continuous basis under its Registration Statements on Form S-3 (No. 33-
53327, No. 33-61339, No. 33-60069 and No. 333-86363). Under Item 5, "Other
Events," the Registrant filed a press release entitled "DuPont Reviews
Progress Toward Double-Digit Earnings Growth."

SIGNATURES

Pursuant to the requirements of Section 13 of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized and in the capacities indicated, as
of the 17th day of March 2000.

E. I. DU PONT DE NEMOURS AND COMPANY
(Registrant)

G. M. Pfeiffer
By __________________________________
G. M. Pfeiffer
Senior Vice President--DuPont
Finance
(Principal Financial and
Accounting Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed as of the 17th day of March 2000, by the following
persons on behalf of the registrant in the capacities indicated:

Chairman of the Board and Chief Executive Officer
and Director:
(Principal Executive Officer):

C. O. Holliday, Jr.
---------------------
C. O. Holliday, Jr.

Directors:

A. J. P. Belda G. Lindahl
- ------------------------------------- -------------------------------------
A. J. P. Belda G. Lindahl

C. J. Crawford M. Naitoh
- ------------------------------------- -------------------------------------
C. J. Crawford M. Naitoh

L. C. Duemling W. K. Reilly
- ------------------------------------- -------------------------------------
L. C. Duemling W. K. Reilly

E. B. du Pont H. R. Sharp, III
- ------------------------------------- -------------------------------------
E. B. du Pont H. R. Sharp, III

D. C. Hopkins C. M. Vest
- ------------------------------------- -------------------------------------
D. C. Hopkins C. M. Vest

L. D. Juliber S. I. Weill
- ------------------------------------- -------------------------------------
L. D. Juliber S. I. Weill

REPORT OF INDEPENDENT ACCOUNTANTS ON
FINANCIAL STATEMENT SCHEDULE

To the Board of Directors of
E. I. du Pont de Nemours and Company

Our audits of the consolidated financial statements referred to in our
report dated February 18, 2000, appearing on page 42 of the 1999 Annual Report
to Stockholders of E. I. du Pont de Nemours and Company, (which report and
consolidated financial statements are incorporated by reference in this Annual
Report on Form 10-K) also included an audit of the Financial Statement
Schedule listed in Item 14(a)2 of this Form 10-K. In our opinion, this
Financial Statement Schedule presents fairly, in all material respects, the
information set forth therein when read in conjunction with the related
consolidated financial statements.

PRICEWATERHOUSECOOPERS LLP

Thirty South Seventeenth Street
Philadelphia, Pennsylvania 19103
February 18, 2000

E. I. DU PONT DE NEMOURS AND COMPANY
AND CONSOLIDATED SUBSIDIARIES

SCHEDULE II--VALUATION AND QUALIFYING ACCOUNTS AND RESERVES
For the Years Ended December 31
(Dollars in millions)
- --------------------------------------------------------------------------------

Column A Column B Column C Column D Column E
- -------- ---------- ----------- ------------- --------------
Balance at
Beginning Additions Deductions Balance at End
Description of Year to Reserves from Reserves of Year
- ----------- ---------- ----------- ------------- --------------

1999
EMPLOYEE SEPARATION COSTS
AND WRITE-DOWN OF ASSETS
Write-down of Assets..... $161 $ - $161(b) $ -
Employee Termination
Benefits/Other People-
Related Costs........... 184 122(a) 207(c) 99
Other.................... 48 29(a) 37(d) 40
1998
EMPLOYEE SEPARATION COSTS
AND WRITE-DOWN OF
ASSETS(e)
Write-down of Assets..... $233 $232(a) $304(f) $161
Employee Termination
Benefits/Other People-
Related Costs........... 53 310(a) 179(f) 184
Other.................... 54 35(a) 41(f) 48
1997
EMPLOYEE SEPARATION COSTS
AND WRITE-DOWN OF ASSETS
Write-down of Assets..... $ - $233(a) $ - $233
Employee Termination
Benefits/Other People-
Related Costs........... - 53(a) - 53
Other.................... - 54(a) - 54

- --------
(a) Additions represent charges to profit and loss.
(b) Deductions represent facility shutdowns of $130 and credits to profit and
loss of $31.
(c) Deductions include settlement of employee separation reserves of $177 and
credits to profit and loss of $30.
(d) Deductions include settlement of other reserves of $21 and credits to
profit and loss of $16.
(e) Certain amounts have been reclassified to conform with 1999 presentation.
(f) Deductions represent settlement of employee separations and asset write-
offs.

E. I. DU PONT DE NEMOURS AND COMPANY
INDEX OF EXHIBITS

Exhibit
Number Description
------- -----------

- --------
* Management contract or compensatory plan or arrangement required to be filed
as an exhibit to this Form 10-K.

Exhibit
Number Description
------- -----------

- --------
* Filed electronically only.